Holdings
Sofinnova Investments, Inc.
As of Jun 30, 2026, Sofinnova Investments, Inc. reported 48 positions worth US$1.7B. Largest: Natera, Inc., Vera Therapeutics, Inc. and Genmab A/s. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Natera, Inc. | 1.55M | US$421M | no change | Jun 30, 2026 |
| Vera Therapeutics, Inc. | 2.79M | US$120M | no change | Jun 30, 2026 |
| Genmab A/s | 4.05M | US$111M | +3.29M | Jun 30, 2026 |
| Rapport Therapeutics, Inc. | 1.9M | US$79.4M | no change | Jun 30, 2026 |
| Seaport Therapeutics, Inc. | 3.56M | US$77.4M | new | Jun 30, 2026 |
| Arrivent Biopharma, Inc. | 1.7M | US$58.9M | no change | Jun 30, 2026 |
| Ultragenyx Pharmaceutical Inc. | 1.72M | US$57.3M | −1.43M | Jun 30, 2026 |
| Bioage Labs, Inc. | 2.29M | US$56.2M | no change | Jun 30, 2026 |
| Bristol-myers Squibb Company | 877K | US$50.5M | −1.11M | Jun 30, 2026 |
| Supernus Pharmaceuticals, Inc. | 1.04M | US$48.2M | +82,019 | Jun 30, 2026 |